Recombinant Retrovirus Envelope Segmentation for Gene Delivery
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current gene therapy methods face challenges in precisely delivering genes to specific cells or organs in vivo due to difficulties in targeting viral vectors, leading to low viral titers and inefficient fusion functions when altering the envelope glycoprotein for cell specificity.
Innovation Solution
Development of recombinant retroviruses with a fusogenic molecule and a cell-specific binding determinant, allowing for precise targeting and efficient delivery of genes to target cells by separating viral binding and fusion functions, maintaining high viral titer and specificity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Adaptability or versatility
If the envelope glycoprotein is altered to target specific cell types, then cell specificity is improved, but viral titer and fusion function deteriorate
Solution Approach 1:
The invention divides the envelope glycoprotein into two separate components: a cell-specific binding determinant (such as a ligand or antibody) and a fusogenic molecule (such as VSV-G). The binding determinant is responsible for specific attachment to target cells, while the fusogenic molecule mediates membrane fusion and viral entry. This segmentation allows each component to perform its specialized function independently, maintaining high viral titers while achieving cell-specific targeting.
Solution Approach 2:
The fusogenic molecule (e.g., VSV-G) serves as a universal component that can be combined with different cell-specific binding determinants to create targeted vectors for various cell types. This multi-functional approach allows the same fusogenic molecule to work across different targeting scenarios, maintaining consistent fusion efficiency while adapting to different target specificities.
2Adaptability or versatility
If the envelope glycoprotein is altered to target specific cell types, then cell specificity is improved, but fusion efficiency deteriorates
Solution Approach 1:
By separating the binding function from the fusion function in the envelope glycoprotein, the invention allows the fusogenic molecule to maintain its native fusion efficiency while the binding determinant provides cell specificity. The fusogenic molecule (such as VSV-G) is not compromised by targeting modifications because it operates independently after the binding determinant has attached the virus to the target cell.
3Adaptability or versatility
If complex env with a ligand protein or antibody to form a bridge, then cell targeting is improved, but fusion efficiency deteriorates
Solution Approach 1:
Instead of creating a complex bridge structure that couples binding and fusion functions, the invention uses a simplified segmentation approach where the binding determinant and fusogenic molecule are separate but coordinated components. This avoids the structural complexity and functional interference that plague bridge-based approaches.
Solution Approach 2:
The invention uses the cell-specific binding determinant as an intermediary that mediates attachment without directly participating in fusion. This intermediary approach allows the fusogenic molecule to perform fusion independently, avoiding the fusion inefficiencies that occur when binding and fusion are mechanically coupled in bridge-based systems.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach enables efficient and specific gene delivery to target cells, reducing off-target effects and enhancing therapeutic potential, while maintaining high viral titer and specificity, thus overcoming existing challenges in viral vector targeting and fusion efficiency.
Implementation Method 1
The fusogenic molecule is preferably pH sensitive. Preferably the pH sensitivity is such that the fusogen is able to mediate delivery of the viral core across the membrane in the endocytic compartment of a target cell.
Implementation Method 2
The cell-specific binding determinant is preferably a protein, and in some embodiments is an antibody. The cell-specific binding determinant may comprise more than one molecule.
Data Source
AI summary
Methods and compositions are provided for delivering a polynucleotide encoding a gene of interest to a target cell using a virus. The virus envelope comprises a cell-specific binding determinant that recognizes and binds to a component on the target cell surface, leading to endocytosis of the virus. A separate fusogenic molecule is also present on the envelope and facilitates delivery of the polynucleotide across the membrane and into the cytosol of the target cell. The methods and related compositions can be used for treating patients having suffering from a wide range of conditions, including infection, such as HIV; cancers, such as non-Hodgkin's lymphoma and breast cancer; and hematological disorders, such as severe combined immunodeficiency.